Search
Kura Oncology Inc
KURAAdd to Watchlist
9.860USD
-0.020-0.20%
Close 10-21 16:00（ET）
875.27MMarket Cap
LossP/E TTM
Kura Oncology Inc (KURA) Stock Price Target & Forecast
Analyst Rating
Based on 16 analysts giving stock ratings to Kura Oncology Inc in the past month.
Buy
4 Strong Buy
11 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
31.846USD+250.73%
KURA Analyst Recommendation Trends
In the current month, KURA has received 11 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KURA average Analyst price target in the last month is 31.846.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
4
4
4
4
4
4
4
4
11
11
10
10
10
10
9
9
1
1
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16
16
16
16
16
16
15
15
KURA Analyst Rating for Peer Comparison
Updated: Oct 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Biontech SE
BNTX
4
12
8
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Financial Forecasting
Based on analysts' estimates, KURA EPS is projected to reach -0.824 in FY2026Q3, following reported EPS of -0.769 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.48
-0.63
-0.88
-0.82
-0.82
Actual
-0.92
-0.83
-0.77
--
--
Surprise
-89.70%
-30.76%
+12.39%
--
--
FAQs
What is Kura Oncology Inc's expected revenue for the next quarter?
Kura Oncology Inc's expected revenue is 23.60M.
What is Kura Oncology Inc's price target?
Analysts forecast that Kura Oncology Inc's price target is USD 31.85, with the highest forecast at USD 76.00 and the lowest forecast at USD 15.00.
How have Kura Oncology IncKURA's recent earnings per share performed?
The market expectation was USD -0.77, while Kura Oncology IncKURA's earnings per share (EPS) for the previous quarter was USD -0.83. EPS for the next quarter is expected at USD -0.82.
What is the analyst rating for Kura Oncology Inc?
Based on the ratings of Kura Oncology Inc's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.